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Summary: A radioimmunoassay for the measurement of cyclic somatostatin is described. Synthetic somatostatin was
conjugated with bovine serum albumin or human serum -globulin using glutaraldehyde as the coupling reagent. Anti-
sera were raised in rabbits injected with the hapten-bovine serum albumin-, or with the hapten-human serum a-globulin-
conjugate.
Since somatostatin lacks a tyrosine residue that can be readily iodinated, three different radiolabeling procedures for
synthetic cyclic Tyr^som'atostatin were compared with each other. In addition, cyclic somatostatin was radiolabeled
with the Bolton-Hunter reagent. The radiolabeled antigens were purified by G-25 Sephadex adsorption chromato-
graphy and thus separated from unreacted components. Maximal yields were achieved when Tyr1-somatostatin was
iodinated with chloramine-T the largest immunochemical reactivity, however, was obtained by applying the lactoper-
oxidase-catalysed iodination with 125I. Iodinated somatostatin-derivatives adsorbed onto an inorganic as well as an
organic matrix; the percentage of non-specific binding was 14%.
The radioimmunoassay was performed with an antiserum dilution of 1:5000. Displacement of labeled cyclic Tyr1-
somatostatin by cold cyclic somatostatin was optimal with the use of 25—33.3 kBq/1 and was in the range of
6 pmol/1—6 nmol/1. Ocytocin, (lys)-vasopressin, (arg)-vasopressin, valinomycin, polymyxin, insulin, glucagon, human
growth hormone (somatotropin), luteinizing hormone-releasing hormone (luliberin), and thyrotropin releasing
hormone (thyroliberin) — each 10 g/l — do not interfere with the radioimmunoassay. Linear somatostatin shows a
weaker affinity to the antibody than cyclic somatostatin. Recovery of cyclic somatostatin added to human plasma,
cerebrospinal fluid, pancreatic, hypothalainic, and pituitary tissue ranged from 77 to 84% when reextracted with acid
acetone.
Using the method described, native cyclic somatostatin in human plasma could not be detected. We were able to
detect 116 ± 12 ng/1 somatostatin in the acid acetone extract of freeze-dried cerebrospinal fluid from 4 healthy
persons.
Radioimmunoassay fur zyklisches Somatostatin:
Antikörpergewinnung, vergleichende Radiojod-Markierung und dose-respönse-Kurve
Zusammenfassung: Eine radioimmunologische Methode zum Nachweis von cyclischem Somatostatin wird beschrie-
ben. Synthetischeis Somatostatin wurde zur Immunogendärstelluiig an Rinderserumalbumin und menschliches -Glo-
bulin mittels Glutaraldehyd gebunden. Sowohl mit Hapten-Rinder-Serumalbumin- als auch mit Hapten-Serum-a-Glo-
bulimKonjugat konnte Antiserum in Kaninchen erzeugt werden.
Da Somatostatin kein Tyrosin besitzt, das direkt jodiert werden könnte, wurde einerseits Tyr1-Somatostatin nach
verschiedener Methodik radiomarkiert. Andererseits wurde Somatostatin mit dem Bolton-Hunter-Reagenz markiert.
Die Antigene wurden durch AdsorptionschiQmatQgraphie über eine G-25-Sephadex Säule nachgereinigt. Die höch-
sten Ausbeuten wurden bei Jodierung von Tyr1-Somatostatin mit Hilfe von Chloramin-T, die höchste immunoche-
mische Reaktivität dagegen durch Lactoperoxidase katalysierte Jodierung mit12S J erzielt. Jodierte Somatostatin-
Derivate adsorbieren leicht an anorganischer wie auch organischer Matrix. Der Prozentsatz der unspezifischen Bin-
dung liegt bei 14%.
Der Radioimmunoassay wurde mit l :5000 verdünntem Antiserum durchgeführt. Verdrängung mit cyclischem So-
matostatin ist bei Einsatz von 25-33 kBq/1 optimal und liegt im Bereich von 6 pmol/1-6 nmol/1. Ocytocin, (Lys)-
und (Arg>Vasopressin, Valinomycin, Polymyxin, Insulin, Glucagon, menschliches Wachstumshormon (Somatotropin),
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Luliberin und Thyroliberin - je 10 Mg/1 - stören die immunochemische Bindung von Somatostatin nicht. Lineares
Somatostatin bewirkt eine schwache Verdrängung.
Mit der hier beschriebenen Methode ist die direkte Messung von cyclischem Somatostatin in menschlichem Serum
bisher nicht möglich. Andererseits kann Somatostatin, das zu Serum oder anderem biologischen Material hinzugege-
ben wurde, mittels Extraktion zu 77-84% wiedergefunden werden.
In cerebrospinalem Liquor 4 gesunder Personen wurden 116 ± 12 ng/1 cyclisches Somatostatin aus sauren Aceton-
extrakten der gefriergetrockneten Proben nachgewiesen.
Introduction
Somatostatin is a tetradecapeptide hormone which was
recently isolated from sheep (1) and porcine hypothalami
(2). The chemical synthesis of somatostatin in 1973 (1)
provided the basis for the further analytical, physiologi-
cal and pharmacological investigation of this hormone.
Somatostatin inhibits many endocrine and exocrine
secretions as well as hormone production in neoplasms
(3,4, 5). Endogenous somatostatin has been detected
qualitatively by histoimmunochemical techniques in
cerebral (6), pancreatic (7), and gastrointestinal tissue
(8). The application of quantitative radioimmunological
techniques has proved to be difficult, perhaps due to
the very small concentrations of the hormone in organs
and serum. In addition, the short biological half life (9)
and occurrence of higher aggregations withsomatosta-
tin-like physiological effects (2,10) represent additional
complicating factors.
Therefore, it was one purpose of this work to develop a
specific, sensitive radioimmunoassay for cyclic somato-
statin. Since somatostatin must be derivatised before
radiolabeling with 125I, various radioiodination proce-
dures were performed and the immunochemical binding
with antibodies was compared.
In this study we present results for the recovery and
measurement of cyclic somatostatin in extracts of
freeze-dried human cerebrospinal fluid.
Acid acetone extraction solution (extract solution): 0.42 mo 1/1
acetic acid/acetone (volumes, 100 ml + 100 ml) Charcoal,
Norit A (Serva, Heidelberg), was coated with 15% dextran
T 70 and diluted to 2.5 g/1 in 0,01 mol/1 sodium phosphate in
0.14 mol/1 NaCl, pH 7.0.
Glassware was methylsilanicated with dichlordimethylsilane —
100 ml/1 in benzene - by l h treatment at room temperature.
Immunogen synthesis
Somatostatin-human serum -globulin- and somätostatin-bovine
serum albumin-conjugate were synthesized according to Habeeb
&Hiramoto (11). Cytochrome c was condensed as a model pro-
tein to synthetic cyclic somatostatin in the hollow fiber dialyse
beaker b/HFD-1/20 (Serva, Heidelberg) and the products of the
reaction were separated by Ultrogel AcA 54 gel filtration: 0.5 ml
aliquots of the reaction mixture were eluted at various reaction
times with 0.05 mol/1 sodium phosphate, pH 7, and the adsorp-
tion was measured at 280 nm.
After 3h the rest of the reaction mixture was dialysed for 30 min
against a total of 300 ml water at a throughput quota of 10 ml/
min. By this means, the hapten ligand complex was purified
and then freeze-dried and stored at 8 9C.
Antibodies
8 rabbits were immunized by subcutaneous multiple injections
of the following immunogenic suspension: One dose contained
1 ml somatostatin-conjugate consisting of 120 Mg hapten (anti-
gen), 2.5 mg mycobacterium tuberculosis (dried cell walls from
RoberMCoch-Institute, Berlin), 2 · 109 pertussis vaccine (Well-
come, England) in 0.5 ml 0.14 mol/1 NaCl and 0.5 ml complete
Freund* s adjuvant (Difco, USA). Booster injections were done
at 2-3 week intervals with the immunogen suspension alone
without additional mycobacteriae and pertussis bacteriae. Blood
was drawn from the ear vein at 2-3 day intervals beginning
6 days after the second booster, the heparinized antiserum was
frozen in 0.1 ml batches and stored at - 20 °C
Materials and Methods
The following materials were obtained from commercial sources:
Cyclic somatostatin, linear somatostatin, and cyclic Tyr1-so-
matostatin (Serono, Freiburg); Na1251 and Nai311 (Amersham-
Buchler, Braunschweig); Bolton-Hunter reagent (NEN, Drei-
eichenhain); human serum -globulin (Sigma, USA); bovine
serum albumin (Serva, Heidelberg); Sephadex G-25 (Pharmacia,
Frankfurt); Ultrogel AcA 54 (LKB, Berlin) Cellulose acetate
foil 30 X 100 (Sartorius, Göttingen); all other chemicals were
obtained from Merck (Darmstadt) or Boehringer (Mannheim)
unless mentioned otherwise within the text. 8 adult rabbits,
mixed-bred and with a minimum weight of 4 kg, were obtained
from Wulf (Königslutter).
Buffers and solutions
Elution buffer (buffer 1): 0.05-0.2 mol/1 ammonium acetate,
1 g/1 gelatine, pH 6.7;
Dilution buffer (buffer 2): 0.01 mol/1 sodium phosphate,
0.14 mol/1 NaCl, 10 mmol/1 EDTA, lg/1 gelatine, pH 7.5;
Radiolabeling
Five different radioiodination techniques were carried out
according to the following methods:
a) Chloramine-f oxidation of12SI with somatostatin; Green-
wood, Hunter & Glover (12);
b) Acylation of somatostatin with N-succinimidyl-3-(4-hy-
droxy-[3-125I]-phenyl)-proprionate;/to/fOH & Hunter (13);
c) Chloramine-T oxidation of Tyr ̂ somatostatin; Greenwood,
Hunter & Glover (12);
d) Lactoperoxidase/H202 oxidation of12SI with Tyr * -soma-
tostatin; Marchalonis (14);
e) Lactoperoxidase/glucose oxidase-glucose oxidation of12SI
with Tyr^somatostatin; Marshall & Odell (16).
Standard labeling of Tyr^somatostatin was performed according
to the combined procedures d) and e): Cyclic Tyr1-somatostatin
was iodinated with 12SI which is oxidised by the lactqperoxidase/
H202 system (d). Excess12SI was removed by anion exchange
resin (e). The experimental conditions for standard radioiodina-
tion assay are summarized in Table 1.
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Tab. 1. Radioiodination of Tyr1 -somatostatin by the lactoper-
oxidase-H2O2-system.
10 μΐ = 4 μ§
20 μΐ
10 μΐ = 37 MBq (l mCi)
5 μΐ = 50 ng
cyclic Tyr * -somatostatin
in 1.2 mmol/1 acetic acid







stop: 500 μΐ = 100 mg Dowex l Χ 10
(Serva, Heidelberg)
in ice-cold buffer I
* Suspension from Boehringer (Mannheim)
Tab. 2. Standard radioimmunoassay for cyclic somatostatin.
600- Ο μΐ buffer 2
100 μΐ antiserum IA2, l: 5000 in buffer 2
100 μΐ [ 12SI]Tyr1-somatostatin, ca. 33.3 Bq in buffer 2
1-500 μΐ somatostatin, 6.14-3068 pmol/1 or
neutralized sample extract in buffer 2
The resin was separated by centrifugation and washed with
1 ml of extract solution. The combined supernatants were used
for further purification by column chromatography.
Adsorption chromatography
For further purification of the radiolabeled antigen 0.8-1.6 ml
of the reaction mixture were separated at room temperature via
a 1.5 X 30 cm Sephadex O25 column within 1.5 h. For elution
a 0.05-0.2 mol/1 buffer 1 was used. 2.3 ml fractions were
collected and aliquots were measured in the scintillation counter
(Packard, USA).
Cellulose acetate foil electrophoresis
5 μΐ of the reaction mixture were separated at 250 V and
2 mA/foil in 0.1 mol/1 barbitural buffer, pH 8.4. Electropho-
resis was allowed to proceed for 25 min, with constant cooling
with tap water. The foil was cut into 5 mm pieces and radio-
activity was measured.
Radipimmunp ssay and charcoal separation
Methylsilanicated glass vials were used for antigen dilution and
radioimmunoassay. Labeled somatostatin was diluted with
buffer 2 to approximately 333 k?q/l immediately after G-25
separation. Samples of cerebrospinal fluid or of other tissue
were treated with extract solution prior to the radioimmunp^
assay. All frozen and fteeze-^dried-serum- and tissue-suspensions
were shaken with extract solution for 5 min t room tempera^
ture, neutralized with 0.1 mol/1 NaOH, and diluted in buffer 2.
A standard radioimmunoassay was performed as summarized in
Table 2. After an incubation period of 18 h at 2-4 °C, 1 ml
charcoal suspension was added to each sample, placed in the
ice^bath for 30 min, centrifuged and washed with 1 ml char-
coal-buffer.
Supernatant, washing solution, and charcoal were measured
(n = 3-5) in the scintillation counter, and the following values
were calculated:
bound somatostatin (B) = supernantant + washing solution
free somatostatin (F) = charcoal
total somatostatin (T) = supernatant + washing solution +
charcoal.
The quantities of cyclic somatostatin in the unknown sample
extracts were determined by comparison with the standard
dose-response curve.
Extraction of cerebrospinal fluid samples
Approximately 10-20 mg of freeze-dried cerebrospinal fluid
from 4 healthy persons (diagnostic air myelography) were
pooled and dissolved in 1 ml distilled water and treated with
the same volume of extract solution. After shaking for 5 min
at room temperature, the sample was concentrated by evapora-
tion under a stream of air, added to the dilution buffer, and the
pH was recorrected with 0.1 mol/1 NaOH. After this, the radio-
immunoassay was performed under standard conditions.
Results
Immunogen preparation
In order to simplify the preparation of imrnunogen, the
hapten ligand synthesis was carried out in the dialysis
beaker, thus allowing the dialysis to follow immediately
without decanting. A complete demineralisation was
achieved after 30 min. As shown in Figure 1, the glutaral-
dehyde coupling of cyclic somatostatin with proteoligand
cytochrome c was monitored by ultrogel filtration of
the reaction mixture. After 3h reaction time, the soma-
tostatin peak at Vj had completely disappeared. The
cytochrome c-somatostatin conjugate was eluted at
36 ml, and thus appeared slightly earlier than cyto-
chrome c. Vo at 16 ml showed a stronger absorption at
280 nm at the end of the reaction period. This may be
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Fig. 1. Separation of cyclic somatostatin and cytochrome c-soma-
tostatin conjugate at the beginning and at the end
of the coupling reaction.
1 ml reaction mixture was separated with 0.05 mol/1
sodium phosphate at room temperature with an ultrogel
AcA 54 column (1.5 X 30 cm). Absorbance was measured
at 280 nm (Uvicord II, LKB).
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Characterisation of antisera
One of 4 rabbits which were treated with human serum
α-globulin-immunogen (FAj), and one out of another 4
rabbits treated with bovine serum albumin-immunogen
(IA2) developed acceptable antisera. When antiserum
IA2 is diluted 1:5000 it binds approximately 50% of
labeled antigen under standard conditions (FAj
1:2000).
The two rabbits with the high-titre antisera died after 27
(FAj) and 13 weeks (IA2). In contrast to the other
rabbits with no antibodies, both had lost more than a
quarter of their body weight and it is unclear whether
they died due to the specific effect of anti-somatostatin
or not.
In Figure 2 the time saturation curve of antiserum IA2
by iodinated Tyr1-somatostatin is presented. A plateau
of saturation was reached after 18 h under standard
conditions.
Excess IA2 binds maximally 82% of the labeled antigen.
The binding portion of the "blank" sample without
antiserum is approximately 14% (B/T).
Figure 3 shows a Scatchard plot. The association con-
stant of the specific binding is calculated: Kj =
0.9 · 10101/mol. For the strongly pH-dependent (non-
specific) binding the association constant is K2 =
3.2 · 10s 1/mol.
lodination of somatostatin
and Tyr^somatostatin
Iodinated somatostatin-derivatives are strongly adsorbed
to Sephadex G-25. This can be used for purification of
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Fig. 2. Binding of [12SI]Tyr1-somatostatin with antiserum IA2
(1:5000) as a function of time.
0.8 ml were taken from a 15 ml standard assay after
different incubation periods. After charcoal separation,
radioactivity was measured and B/F values were cal-








Fig. 3. Scatchard plot for the binding of [ 125I]Tyr^somato-
statin with antibody IA2.
2-1000 pmol/1 of [1^5I]Tyr^somatostatin were in-
cubated in a standard assay: Specific radioactivity -
18.5 MBq/nmol (0.5 mCi/nmol), KI = 0.9 · 1010 1/mol





Fig. 4. Cellulose acetate foil electrophoresis of the reaction
mixture: after radio labeling of somatostatin *-̂ -·
according to Bolton & Hunter (13), of Tyr1 -somato-
statin ο ο according to this publication, and with
Na131I .
U = 250 V, I = 6 mA, separation time = 25 min in
0.02 mol/i barbital buffer, pH 8.7. Radioactivity was
measured from 5 mm slices of the cellulose acetate foils.
iodination procedures can be compared by Sephadex
G-25 adsorption-chromatography. In addition, the iodina-
tion was monitored by means of cellulose acetate foil
electrophoreses (Fig. 4) and by CMC-ion exchange
chromatography (10).
In Figures 5 a-e the -elation curves of adsorption
chromatography are summarized. Irrim noreactive anti-
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and/or polymerisation of the oxidized ring conforma-
tion of the peptides (16).
When the method ofBolton & Hunter (13), using N-
succinimidyl-3-(4-hydroxy-3-12SI-phenyl)-propionate,
was applied, a yield of 80% in retarded peaks was
measured (Fig. 5b). Here too, however, no immuno-
chemical reactions were detected with antibodies.
The results of the enzymatically catalysed iodination
according to Marchalonis (14) and Marshall & Odell (15)
are shown in Figure 5d and 5e. The yields are lower
than with direct iodine oxidation by chloramine-T. On
the other hand a higher immunochemical reactivity was
achieved.
In Figure 6 the immunochemical binding capacity of
the individual fractions of a Sephadex G-25 separation
is demonstrated (black bars). Based on the fact that all
of the iodinated Tyr^somatostatin appears in the
retarded peak, it can be calculated that a specific radio-
activity of 18.5 MBq/nmol (0.5 mCi/nmol) Tyr1-somato-
statin is obtained. This means that on the average each
fourth labeled Tyr ̂ somatostatin molecule contains one
radioactive 125I-atom. The yields vary greatly from one
separation to the other in the range of 20—50%. Re-
producibility and the best yields could be achieved by
pre-eluting and equilibrating of the Sephadex with gela-
tine and cold I-Tyr1-somatostatin.
For the determination of purity of the labeled antigen,
and for the evaluation of non-specific binding, isoelectric
focussing and disc-polyacrylamide gel electrophoresis
were performed (18). Figure 7 a demonstrates the high
Fig. 5. Comparative adsorption chromatography after radio-
labeling, with
a) 125I~, chloramine-T, and somatostatin (12)
b) N-succinimidyl-3-(4-hydroxy-[3-12SI]phenyl)-pro-
Dio nate, and somatostatin (13)
c)125I~, chloramine-T, and Tyr1 -somatostatin (12)
d) 125I~% lactoperoxidase/HiOj, and Tyr1-somato-
statin (14)
e) 12δί , lactoperoxidase/glucose oxidase, and
Tyr1-somatostatin (15)
The separation took place under standard conditions. In
d) and e) the hatched area indicates immunochemically
reactive somatostatin.
gen appears in the retarded peaks after fraction 30, un-
reacted 125I in fraction 26 and higher aggregates in frac-
tion 10 (dextran blue fraction).
Cyclic somatostatin was labeled using the method of
Greenwood, Hunter & Glover (12), but no radiolabeling
could be demonstrated (Fig. 5 a). In contrast, when
cyclic Tyf1-somatostatin was labeled according to this
method, nearly 100% of the eluted radioactivity was
detected in the retarded fractions of the G-25 chromato-
graphy (Figf 5c). However, no immunochemical
reactivity could be demonstrated. No m-bisulfite was
added as described in the original report of Greenwood,








Fig. 6. Adsorption chromatography elution patterns of cyclic
somatostatin and [^^IJTyr1-somatostatin, which was
labeled under standard conditions.
Cold somatostatin was measured with the Folin-Ciocalteau
phenol reagent (17) ο—-ο and labeled Tyr-somatostatin
by its radioactivity · ·. The B/F values (black bars)
were determined for each fraction with antiserum FA1
(1:2000) according to the standard method. Chromato-
graphie conditions as in Figure 5.
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Fig. 7. Isoelectric focussing of
a) cyclic somatostatin Ampholine pH 3-10 (LKB, Swe-
den), incubation time 24 h at 10 °C, U = 500-600 V
(0.8 m A), 2.5 ml fractions; 1 mg somatostatin was
focussed and the fractions were measured at 280 nm
• β.
b) cyclic [12SI JTyr1 -somatostatin. Fraction 34 of the
G-25 separation (Fig. 5) was focussed and radioactivity
was measured · ·. 2 mg bovine serum albumin
was also focussed and absorption was measured at
280 nm ο ο. Focussing conditions as in a).
purity of synthetic cold cyclic somatostatin and its main
isoelectric point at 9.5. Figure 7b shows the inhomo-
geneity of the iodinated antigen in the alkaline pH range.
In the isoelectric focussing as well as in the disc-poly-
acrylamide gel electrophoresis it could be demonstrated
that radioactivity is bound to bovine serum albumin. The
radioactivity in the pH-range of the bovine serum albumin
peaks contains 6.4% of the applied sample. The radio-
activity in the neutral range possibly originates from
spread iodinated lactoperoxidase.
Recovery of [125I] Ty r ̂ somatostatin
When polystyrene tubes were used, 51 % of the added
radioactivity was adsorbed at the tube surface after two
days incubation time under standard conditions. There-
fore, methyksilanicated glass tubes and pipettes were
used for further work with small quantities of radio-
iodiriated somatostatin. Thus, maximally 5 % of the
radioactivity was retained on the glass tubes as is shown
in table 3. The adsorption of [12SI] Tyr^somatostatin
on the tube surface and the portion of non-specific
binding is demonstrated.
Dose-response curve
and assay of serum and cerebrospinal fluid
Figure 8 demonstrates the standard (dose-response)
curve obtained with antiserum, IA2, diluted 1:5000.
There is specific competition in the rarige of 10-
1000 pg per sample or 6.2 pmol/1 ·*- 6.2 nmol/1 cyclic
somatostatin. The average maximal deviation (from the
mean value) is ± 7.4% (n = 4-5). Cross^reactivity was
observed for linear somatostatin (B/F: 0.8-r0.7 for
1-10 Mg/l). No suppression was detectable after the
addition of 1 μξ/l of either pcytpcin, (lys)-vasopressin
(arg)-vasopressin, valinomycin, polymyxin, insulin,
glucagon, human somatotropin, luliberin or thyroliberin.
When 1 jug/1 somatostatin is added to charcoal-pre-
treated, boiled (5 min) normal serum (Riacon) and
reextracted with 1 ml acid acetone, a dose response
curve of the type shown in Figure 8 is obtained. Acetic
acid acetone extracts from hompgenates of pituitaries
Tab. 3. Adsorption f [^25IlTyr1-som tost tin to the surface
of plastic and glass tubes in the presence of different
solvent systems. All solvent systems have a pH of 7.5,
incubation times 45h at 2-4 °C. total radioactivity
35 Bq/ml and tube. For comparison 0.01 mol/1 Na-
phosphate and 0.01 mol/1 imidazole/HCl were used and
0.5 mmol/1 phenylalanine (Phe) and 10 g/1 bovine serum
albumin (BSA) were added as protecting reagents. Glass
tubes were methyl-silanicated as described in the text











































radioactivity in the supernatant after charcoal separation.
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, 8. Dose response curve of the radioimmunoassay for cyclic
somatostatin.
Antiserum IA2 was used at a dilution of 1:5000. The
concentrations of the added unlabeled somatostatin
were plotted logarithmically on the abscissa. Bound (B)
and free (F) radioactivities were measured after charcoal
treatment and the SEM (n = 4-5) were calculated for
each sample. The displacement of 6.1 pmol/1-31 nmol/1
cyclic somatostatin ο ο (standard curve) is compared
with the displacement of cyclic somatostatin · ·,
which was added to normal serum (Riacon) and then
reextracted. Cross reaction with linear somatostatin
α α is demonstrated. B/F of the nonspecific binding
is 0.17 and B/F value of the sample lacking cold somato-
statin is 0.95.
and hypothalami of the rat and of chicken pancreas
showed a similar dose response relation to that of normal
serum samples.
An increase of B/F-values was observed when the vol-
ume of untreated aqueous cerebrospinal fluid-solution
was raised from 0.04 ml to 0.2 ml per assay tube and
100 ng/1 cyclic somatostatin were added to the cere-
brospinal fluid-solution. This paradoxical effect could
be abolished by extracting freezedried cerebrospinal
fluid with acid acetone as described above.
Table 4 presents the B/F-values obtained when cere-
brospinal fluid from four healthy persons was assayed.
The corresponding somatostatin-eoncentrations are
summarized. A somatostatin concentration of
116 ± 12 ng/1 in cerebrospinal fluid can be evaluated
from the acid acetone extract of freeze-dried samples.
Discussion
This paper describes the development of specific anti-
sera against cyclic somatostatin. Immunizations with
somatostatin-bovine serum albumin as well as somato-
statin-human serum α-globulin glutaraldehyde conjugate
were successful. Although antiserum IA2, generated
with somatostatin-bovine serum albumin-conjiugate,
shows a higher affinity for sprnatostatin, it cannot be
concluded that bovine serum albumin is a better pro-
Tab. 4. Cyclic somatostatin in cerebrospinal fluid (CSF).
Fresh, freeze-dried cerebrospinal fluid was obtained
from 4 healthy persons during diagnostic air myelo-
graphy.
Approximately 20 mg of freeze-dried cerebrospinal fluid
were dissolved in 1 ml distilled H20 and an equal portion
was treated with extract solution as described in the
text.
Radioimmunoassay was performed under standard condi-
tions. For B/F-values, deviations from the mean value


















































teoligand for immunization than human serum α-globu-
lin, because both rabbits (the "bovine serum albumin-
rabbit" and the "human serum α-globulin-rabbit") died
after too short a period of immunization.
Apart from the specificity, the (high) affinity of anti-
bodies to antigen is a limiting factor for the sensitivity
of a radioimmunoassay. Therefore, a Scatchard plot for
IA2 was evaluated and the association constant was
calculated. The high value of KI (0.9 · 1010 1/mol)
indicates the sufficient affinity between IA2 antibody
and [125I] Tyi^-somatostatin. According toArimura
et al. (10), the derivatisation with [125I]Tyr on the
lateral side of the peptide antigen is not disadvantage-
ous for the immunospecificity, since with immuniza-
tion at least one proteolig nd is coupled at the same
molecule side via Ala1.
Our results, however, demonstrate that iodinated Tyr1-
somatostatin shows high non-specific adsorptive
reactivity, thus differing considerably from the ad-
sorptive reactivity of the unlabeled antigen.
Iodinated somatostatin can be separated from the non-
iodinated somatostatin by means of Sephadex gel ad-
sorption chroniatography (Fig. 5). This effect has
already been utilized for the purification of labeled
ocytocin and vasopressin (19,16). Strong adsorption
of iodinated somatostatin to a solid phase can also be
demonstrated with other Chromatographie techniques,
e. g. CMC-ion^exchange (10) and cellulose acetate foil
electrophoresis (18).
Thus hydrophobization of the glassware and pre-elution
of the chromatography columns (with I-Tyr1-somatosta-
tin) was necessary for optimal recovery.
J. Clin. Chem. Clin. Biochem. /Vol. 15,1977 / No. 12
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Under such conditions radiolabeling with a final average
yield of 39% was achieved. This value is higher than the
yield of 14% reported byMiyachi et al. (20) who
labeled luliberin with the lactoperoxidase/H202-method,
but our yield is significantly lower than the yield of
70-80% achieved by Arimura et al. (10). Because of the
high specific radioactivity it can be assumed that in
any case a portion of the labeled antigen is destroyed,
and the derivatives finally interfere with the radio-
immunoassay. The radioimmunoassay described here
has confirmed many of the findings previously reported
by Arimura et al. (10). In particular, the inhibition of
the [125I]Tyr1-somatostatin binding was observed after
the addition of charcoal-washed serum to the radio-
immunoassay. Arimura et al. (10) have suggested that
inhibition by somatostatin-like substances or non-spe-
cific reactions with plasma protein may be responsible
for the insufficient sensitivity.
The fact that no somatostatin could be detected in nor-
mal serum may be due to the insufficient sensitivity. As
is shown in Figure 8, the dose related suppression with
synthetic cyclic somatostatin is in a range similar to the
dose response correlation which was observed by Ari-
mura et al. (10). Mdntosh et al. (21) more recently
reported a sensitivity of 2 ng/1 of their radioimmuno-
assay for somatostatin. The non-specific reactivity of
iodinated Tyr1-somatostatin seems to be another inter-
fering factor as indicated by the high value of K2
(3.2 · 10s 1/mol). Furthermore, experiments with
disc-poly acrylamide gel electrophoresis (18) and iso-
electric focussing (Fig. 7) show that multivalent reacti-
vity with protein is possible. The high value of the
blank, 14% (B/T), indicates the same phenomenon.
The "hairpin loop" structures suggested for cyclic soma-
tostatin byHolladay &Puett (22) offer an explanation
of the multivalent reactivity of cyclic somatostatin
and its cyclic derivatives: One side with the aromatic
residues of the straightened ring-peptide reacts hydro-
phobically, and the other side with hydroxy and acidic
functions reacts hydrophilically. The multivalent
reactivity seems to be increased, when Tyr^somato-
statin is iodinated or native somatostatin is coupled
withp-hydroxy-[125I]phenyl-propionate. With the latter
labeling method (13), however, the absence of specific
binding with antibodies is apparently due to a deriva-
tisation at the free primary lysine amino groups of
somatostatin.
Since somatostatin has been located at ventricular nerve
endings by histoimmunochemical techniques (6) and
elevated somatostatin concentrations in cerebrospinal
fluid of patients with spinal and brain disease have been
reported (23), attempts were made to determine cyclic
somatostatin in cerebrospinal fluid using the techniques
described here.
A similar effect to that observed with human serum, i. e.
initial suppression but no dose-response relationship,
was also observed when fresh human cerebrospinal fluid
was added to the radioimmunoassay.
The opposite effect, a "paradoxical suppression" was
measured when synthetic cyclic somatostatin was added
to the untreated cerebrospinal fluid solutions, which
were then added in increasing volumes to the assay. An
interpretation of this unexpected increase Of B/F-values
is possibly given by the fact that under these experimen-
tal conditions a macromolecular carrier, soluble in cere-
brospinal fluid, is present in higher concentrations and
binds somatostatin in an exponential manner. Moreover,
a higher somatostatin-aggregation (2), induced by soma-
tostatin itself, is possible. This would yield an apparent
lower concentration of monomeric cold antigen in the
radioimmunoassay.
Applying the described acidic acetone extraction pro-
cedure, a dose related response can be achieved. By
comparison with the standard curve (Fig. 8), we deter-
mined 116 ± 12 ng/1 somatostatin in cerebrospinal
fluid of four healthy persons. This value is more than
two and a half time higher than that determined for
normal subjects byPatel,Rao &Reichlin (23)
(42.5 ±5.2 ng/1).
This disagreement seems understandable considering
the variation in sampling procedures, extraction tech-
niques and assay conditions used.
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